Literature DB >> 6321855

Increased sensitivity of cerebrohepatorenal syndrome fibroblasts to antimycin A.

R I Kelley, B E Corkey.   

Abstract

The effect of four mitochondrial electron transport inhibitors on the growth of normal and cerebrohepatorenal syndrome (CHRS) fibroblasts was studied. Compared to normal fibroblasts, CHRS cells demonstrated a fivefold greater sensitivity to antimycin A, an inhibitor of the cytochrome bc1 complex (complex III), but equal inhibition by amytal, rotenone and 2-heptyl-4-hydroxyquinoline-N-oxide. The results suggest a primary or secondary functional deficiency at mitochondrial complex III in fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6321855     DOI: 10.1007/bf02310872

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  13 in total

1.  A FAMILIAL SYNDROME OF MULTIPLE CONGENITAL DEFECTS.

Authors:  P BOWEN; C S LEE; H ZELLWEGER; R LINDENBERG
Journal:  Bull Johns Hopkins Hosp       Date:  1964-06

2.  Mitochondrial electron-transport inhibitors.

Authors:  T P Singer
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

3.  Cerebro-hepato-renal syndrome of Zellweger. A report of eight cases with comments upon the incidence, the liver lesion, and a fault in pipecolic acid metabolism.

Authors:  D M Danks; P Tippett; C Adams; P Campbell
Journal:  J Pediatr       Date:  1975-03       Impact factor: 4.406

4.  The evaluation of infants with the Zellweger (cerebro-hepato-renal) syndrome.

Authors:  K W Gilchrist; E F Gilbert; N T Shahidi; J M Opitz
Journal:  Clin Genet       Date:  1975 May-Jun       Impact factor: 4.438

5.  Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome.

Authors:  S Goldfischer; C L Moore; A B Johnson; A J Spiro; M P Valsamis; H K Wisniewski; R H Ritch; W T Norton; I Rapin; L M Gartner
Journal:  Science       Date:  1973-10-05       Impact factor: 47.728

6.  Screening for organic acidurias and amino acidopathies in newborns and children.

Authors:  R A Chalmers; P Purkiss; R W Watts; A M Lawson
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

7.  The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen.

Authors:  A Boveris; B Chance
Journal:  Biochem J       Date:  1973-07       Impact factor: 3.857

8.  Biochemical studies in the cerebro-hepato-renal syndrome of Zellweger: a disturbance in the metabolism of pipecolic acid.

Authors:  J M Trijbels; L A Monnens; J A Bakkeren; A H Van Raay-Selten; J M Corstiaensen
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

9.  Disturbances in bile acid metabolism of infants with the Zellweger (cerebro-hepato-renal) syndrome.

Authors:  L Monnens; J Bakkeren; G Parmentier; G Janssen; U van Haelst; F Trijbels; H Eyssen
Journal:  Eur J Pediatr       Date:  1980       Impact factor: 3.183

10.  A metabolic disorder similar to Zellweger syndrome with hepatic acatalasia and absence of peroxisomes, altered content and redox state of cytochromes, and infantile cirrhosis with hemosiderosis.

Authors:  H T Versmold; H J Bremer; V Herzog; G Siegel; D B Bassewitz; U Irle; H Voss; I Lombeck; B Brauser
Journal:  Eur J Pediatr       Date:  1977-03-18       Impact factor: 3.183

View more
  3 in total

1.  Lactic acidosis and mitochondrial dysfunction in two children with peroxisomal disorders.

Authors:  R D Holmes; K H Moore; J P Ofenstein; P Tsatsos; F L Kiechle
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

Review 2.  Liver pathology and immunocytochemistry in congenital peroxisomal diseases: a review.

Authors:  F Roels; M Espeel; D De Craemer
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

3.  Disturbed very long chain (C24-C26) fatty acid pattern in fibroblasts of patients with Zellweger's syndrome.

Authors:  L Govaerts; J Bakkeren; L Monnens; J Maas; F Trijbels; W Kleijer
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.